Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Current Progress in Targeting Telomere and Telomerase Enzymes for the Treatment of Cancer

Author(s): Aakriti Garg, Imran Khan, Nidhi and Mohd. Ashif Khan*

Volume 20, Issue 1, 2024

Published on: 22 May, 2023

Page: [26 - 39] Pages: 14

DOI: 10.2174/1573394719666230331113753

Price: $65

conference banner
Abstract

Telomere is the repetitive sequence of non-coding DNA that protects chromosomes from damage. However, with cell division, the length of the telomere gets shortened ultimately leading to cell senescence. Telomere shortening is compensated by the addition of telomeric sequence by telomerase enzyme and thus preventing senescence which may lead to abnormal cell growth and ultimately result in cancer. There might not be a direct effect of telomerase on carcinogenesis, however, the role of telomerase in maintaining the length of telomere and thus tumor growth progression is quite evident. Various studies have reported the significance of telomerase activity in tumor cells. Therefore, targeting the telomerase enzyme can be an effective approach for the management of cancer, and drugs targeting telomerase inhibition are possible therapeutic candidates to be used clinically for the treatment of cancer in the future. Thus, in the current paper, we aim to review various telomerase inhibitors against cancer, challenges in proposing telomerase inhibitors for the treatment of cancer, and future perspectives on developing telomerase inhibitors for the management of cancer.

« Previous Next »
Graphical Abstract

[1]
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer 2021; 149(4): 778-89.
[http://dx.doi.org/10.1002/ijc.33588] [PMID: 33818764]
[2]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71(1): 7-33.
[http://dx.doi.org/10.3322/caac.21654] [PMID: 33433946]
[3]
Vogelstein B, Kinzler KW. The path to cancer-three strikes and you’re out. N Engl J Med 2015; 373(20): 1895-8.
[http://dx.doi.org/10.1056/NEJMp1508811] [PMID: 26559569]
[4]
Krupp G, Bonatz G, Parwaresch R. Telomerase, immortality and cancer. Biotechnol Annu Rev 2000; 6: 103-40.
[http://dx.doi.org/10.1016/S1387-2656(00)06020-8] [PMID: 11193292]
[5]
Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002; 66: 407-25.
[http://dx.doi.org/10.1128/MMBR.66.3.407-425.2002]
[6]
Victorelli S, Passos JF. Telomeres and cell senescence-size matters not. EBioMedicine 2017; 21: 14-20.
[http://dx.doi.org/10.1016/j.ebiom.2017.03.027] [PMID: 28347656]
[7]
Martínez P, Blasco MA. Heart-breaking telomeres. Circ Res 2018; 123(7): 787-802.
[http://dx.doi.org/10.1161/CIRCRESAHA.118.312202] [PMID: 30355079]
[8]
Zalzman M, Meltzer WA, Portney BA, Brown RA, Gupta A. The role of ubiquitination and sumoylation in telomere biology. Curr Issues Mol Biol 2020; 35: 85-98.
[http://dx.doi.org/10.21775/cimb.035.085] [PMID: 31422934]
[9]
Lantuéjoul S, Salon C, Soria JC, Brambilla E. Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer 2007; 120(9): 1835-41.
[http://dx.doi.org/10.1002/ijc.22473] [PMID: 17311257]
[10]
Tümpel S, Rudolph KL. The role of telomere shortening in somatic stem cells and tissue aging: Lessons from telomerase model systems. Ann N Y Acad Sci 2012; 1266(1): 28-39.
[http://dx.doi.org/10.1111/j.1749-6632.2012.06547.x] [PMID: 22901253]
[11]
Fragkiadaki P, Renieri E, Kalliantasi K, et al. Telomerase inhibitors and activators in aging and cancer: A systematic review. Mol Med Rep 2022; 25(5): 158.
[http://dx.doi.org/10.3892/mmr.2022.12674] [PMID: 35266017]
[12]
Trybek T, Kowalik A, Góźdź S, Kowalska A. Telomeres and telomerase in oncogenesis. (Review) Oncol Lett 2020; 20(2): 1015-27.
[http://dx.doi.org/10.3892/ol.2020.11659] [PMID: 32724340]
[13]
Schmidt JC, Cech TR. Human telomerase: Biogenesis, trafficking, recruitment, and activation. Genes Dev 2015; 29(11): 1095-105.
[http://dx.doi.org/10.1101/gad.263863.115] [PMID: 26063571]
[14]
Lu H, Lei Z, Lu Z, et al. Silencing tankyrase and telomerase promotes A549 human lung adenocarcinoma cell apoptosis and inhibits proliferation. Oncol Rep 2013; 30(4): 1745-52.
[http://dx.doi.org/10.3892/or.2013.2665] [PMID: 23933993]
[15]
Amir M, Khan P, Queen A, et al. Structural features of nucleoprotein CST/Shelterin complex involved in the telomere maintenance and its association with disease mutations. Cells 2020; 9(2): 359.
[http://dx.doi.org/10.3390/cells9020359] [PMID: 32033110]
[16]
Mir SM, Samavarchi Tehrani S, Goodarzi G, et al. Shelterin complex at telomeres: Implications in ageing. Clin Interv Aging 2020; 15: 827-39.
[http://dx.doi.org/10.2147/CIA.S256425] [PMID: 32581523]
[17]
Shay JW. Telomeres and aging. Curr Opin Cell Biol 2018; 52: 1-7.
[http://dx.doi.org/10.1016/j.ceb.2017.12.001] [PMID: 29253739]
[18]
Doksani Y. The response to dna damage at telomeric repeats and its consequences for telomere function. Genes 2019; 10(4): 318.
[http://dx.doi.org/10.3390/genes10040318] [PMID: 31022960]
[19]
Smith EM, Pendlebury DF, Nandakumar J. Structural biology of telomeres and telomerase. Cell Mol Life Sci 2020; 77(1): 61-79.
[http://dx.doi.org/10.1007/s00018-019-03369-x] [PMID: 31728577]
[20]
Abreu E, Aritonovska E, Reichenbach P, et al. TIN2-tethered TPP1 recruits human telomerase to telomeres in vivo. Mol Cell Biol 2010; 30(12): 2971-82.
[http://dx.doi.org/10.1128/MCB.00240-10] [PMID: 20404094]
[21]
Zaug AJ, Podell ER, Nandakumar J, Cech TR. Functional interaction between telomere protein TPP1 and telomerase. Genes Dev 2010; 24(6): 613-22.
[http://dx.doi.org/10.1101/gad.1881810] [PMID: 20231318]
[22]
Chen YA, Shen YL, Hsia HY, Tiang YP, Sung TL, Chen LY. Extrachromosomal telomere repeat DNA is linked to ALT development via cGAS-STING DNA sensing pathway. Nat Struct Mol Biol 2017; 24(12): 1124-31.
[http://dx.doi.org/10.1038/nsmb.3498] [PMID: 29106411]
[23]
Hu C, Rai R, Huang C, et al. Structural and functional analyses of the mammalian TIN2-TPP1-TRF2 telomeric complex. Cell Res 2017; 27(12): 1485-502.
[http://dx.doi.org/10.1038/cr.2017.144] [PMID: 29160297]
[24]
Rajavel M, Orban T, Xu M, et al. Dynamic peptides of human TPP1 fulfill diverse functions in telomere maintenance. Nucleic Acids Res 2016; 44(21): gkw846.
[http://dx.doi.org/10.1093/nar/gkw846] [PMID: 27655633]
[25]
Nandakumar J, Bell CF, Weidenfeld I, Zaug AJ, Leinwand LA, Cech TR. The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity. Nature 2012; 492(7428): 285-9.
[http://dx.doi.org/10.1038/nature11648] [PMID: 23103865]
[26]
Lim CJ, Cech TR. Shaping human telomeres: From shelterin and CST complexes to telomeric chromatin organization. Nat Rev Mol Cell Biol 2021; 22(4): 283-98.
[http://dx.doi.org/10.1038/s41580-021-00328-y] [PMID: 33564154]
[27]
Zhong FL, Batista LFZ, Freund A, Pech MF, Venteicher AS, Artandi SE. TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends. Cell 2012; 150(3): 481-94.
[http://dx.doi.org/10.1016/j.cell.2012.07.012] [PMID: 22863003]
[28]
Rangan A, Fedoroff OY, Hurley LH. Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule. J Biol Chem 2001; 276(7): 4640-6.
[http://dx.doi.org/10.1074/jbc.M005962200] [PMID: 11035006]
[29]
Nakashima M, Nandakumar J, Sullivan KD, Espinosa JM, Cech TR. Inhibition of telomerase recruitment and cancer cell death. J Biol Chem 2013; 288(46): 33171-80.
[http://dx.doi.org/10.1074/jbc.M113.518175] [PMID: 24097987]
[30]
Grill S, Padmanaban S, Friedman A, et al. TPP1 mutagenesis screens unravel shelterin interfaces and functions in hematopoiesis. JCI Insight 2021; 6(9): e138059.
[http://dx.doi.org/10.1172/jci.insight.138059] [PMID: 33822766]
[31]
Shay JW, Wright WE. Senescence and immortalization: Role of telomeres and telomerase. Carcinogenesis 2005; 26(5): 867-74.
[http://dx.doi.org/10.1093/carcin/bgh296] [PMID: 15471900]
[32]
Criqui M, Qamra A, Chu TW, et al. Telomere dysfunction cooperates with epigenetic alterations to impair murine embryonic stem cell fate commitment. eLife 2020; 9: e47333.
[http://dx.doi.org/10.7554/eLife.47333] [PMID: 32297856]
[33]
Razgonova M, Zakharenko A, Golokhvast K, et al. Telomerase and telomeres in aging theory and chronographic aging theory. (Review) Mol Med Rep 2020; 22(3): 1679-94.
[http://dx.doi.org/10.3892/mmr.2020.11274] [PMID: 32705188]
[34]
Kazemi Noureini S, Fatemi L, Wink M. Telomere shortening in breast cancer cells (MCF7) under treatment with low doses of the benzylisoquinoline alkaloid chelidonine. PLoS One 2018; 13(10): e0204901.
[http://dx.doi.org/10.1371/journal.pone.0204901] [PMID: 30281650]
[35]
Ozturk M, Li Y, Tergaonkar V. Current insights to regulation and role of telomerase in human diseases. Antioxidants 2017; 6(1): 17.
[http://dx.doi.org/10.3390/antiox6010017] [PMID: 28264499]
[36]
Noureen N, Wu S, Lv Y, et al. Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation. Nat Commun 2021; 12(1): 139.
[http://dx.doi.org/10.1038/s41467-020-20474-9] [PMID: 33420056]
[37]
Seimiya H, Nagasawa K, Shin-ya K. Chemical targeting of G-quadruplexes in telomeres and beyond for molecular cancer therapeutics. J Antibiot 2021; 74(10): 617-28.
[http://dx.doi.org/10.1038/s41429-021-00454-x] [PMID: 34285374]
[38]
Rao YK, Kao TY, Wu MF, Ko JL, Tzeng YM. Identification of small molecule inhibitors of telomerase activity through transcriptional regulation of hTERT and calcium induction pathway in human lung adenocarcinoma A549 cells. Bioorg Med Chem 2010; 18(19): 6987-94.
[http://dx.doi.org/10.1016/j.bmc.2010.08.021] [PMID: 20813535]
[39]
Jaiswal RK, Yadava PK. Assessment of telomerase as drug target in breast cancer. J Biosci 2020; 45(1): 72.
[http://dx.doi.org/10.1007/s12038-020-00045-2] [PMID: 32515354]
[40]
Ding X, Cheng J, Pang Q, et al. BIBR1532, a Selective telomerase inhibitor, enhances radiosensitivity of non-small cell lung cancer through increasing telomere dysfunction and ATM/CHK1 inhibition. Int J Radiat Oncol Biol Phys 2019; 105(4): 861-74.
[http://dx.doi.org/10.1016/j.ijrobp.2019.08.009] [PMID: 31419512]
[41]
Lü MH, Deng JQ, Cao YL, Fang DC, Zhang Y, Yang SM. Prognostic role of telomerase activity in gastric adenocarcinoma: A meta-analysis. Exp Ther Med 2012; 3(4): 728-34.
[http://dx.doi.org/10.3892/etm.2012.471] [PMID: 22969960]
[42]
Duarte MC, Babeto E, Leite KRM, et al. Expression of TERT in precancerous gastric lesions compared to gastric cancer. Braz J Med Biol Res 2011; 44(2): 100-4.
[http://dx.doi.org/10.1590/S0100-879X2010007500143] [PMID: 21180888]
[43]
Borah S, Xi L, Zaug AJ, et al. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 2015; 347(6225): 1006-10.
[http://dx.doi.org/10.1126/science.1260200] [PMID: 25722414]
[44]
Graham MK, Meeker A. Telomeres and telomerase in prostate cancer development and therapy. Nat Rev Urol 2017; 14(10): 607-19.
[http://dx.doi.org/10.1038/nrurol.2017.104] [PMID: 28675175]
[45]
Joseph I, Tressler R, Bassett E, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 2010; 70(22): 9494-504.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-0233] [PMID: 21062983]
[46]
Barthel FP, Wei W, Tang M, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet 2017; 49(3): 349-57.
[http://dx.doi.org/10.1038/ng.3781] [PMID: 28135248]
[47]
Sekaran V, Soares J, Jarstfer MB. Telomere maintenance as a target for drug discovery. J Med Chem 2014; 57(3): 521-38.
[http://dx.doi.org/10.1021/jm400528t] [PMID: 24053596]
[48]
Stewart SA, Weinberg RA. Telomeres: Cancer to human aging. Annu Rev Cell Dev Biol 2006; 22(1): 531-57.
[http://dx.doi.org/10.1146/annurev.cellbio.22.010305.104518] [PMID: 16824017]
[49]
Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010; 31(1): 9-18.
[http://dx.doi.org/10.1093/carcin/bgp268] [PMID: 19887512]
[50]
Shay JW, Wright WE. Role of telomeres and telomerase in cancer. Semin Cancer Biol 2011; 21(6): 349-53.
[http://dx.doi.org/10.1016/j.semcancer.2011.10.001] [PMID: 22015685]
[51]
Shay JW. Role of telomeres and telomerase in aging and cancer. Cancer Discov 2016; 6(6): 584-93.
[http://dx.doi.org/10.1158/2159-8290.CD-16-0062] [PMID: 27029895]
[52]
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-74.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID: 21376230]
[53]
Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266(5193): 2011-5.
[http://dx.doi.org/10.1126/science.7605428] [PMID: 7605428]
[54]
Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14(17): 4240-8.
[http://dx.doi.org/10.1002/j.1460-2075.1995.tb00098.x] [PMID: 7556065]
[55]
Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33(5): 787-91.
[http://dx.doi.org/10.1016/S0959-8049(97)00062-2] [PMID: 9282118]
[56]
Guterres AN, Villanueva J. Targeting telomerase for cancer therapy. Oncogene 2020; 39: 5811-24.
[http://dx.doi.org/10.1038/s41388-020-01405-w]
[57]
Colgin LM, Wilkinso C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2000; 2(5): 426-32.
[http://dx.doi.org/10.1038/sj.neo.7900112] [PMID: 11191109]
[58]
Aisner D, Wright WE, Shay JW. Telomerase regulation: Not just flipping the switch. Curr Opin Genet Dev 2002; 12(1): 80-5.
[http://dx.doi.org/10.1016/S0959-437X(01)00268-4] [PMID: 11790559]
[59]
Plyasova AA, Zhdanov DD. Alternative splicing of human telomerase reverse transcrIPTASE (hTERT) and its implications in physiological and pathological processes. Biomedicines 2021; 9(5): 526.
[http://dx.doi.org/10.3390/biomedicines9050526] [PMID: 34065134]
[60]
Khattar E, Tergaonkar V. Transcriptional Regulation of Telomerase Reverse Transcriptase (TERT) by MYC. Front Cell Dev Biol 2017; 5: 1.
[http://dx.doi.org/10.3389/fcell.2017.00001] [PMID: 28184371]
[61]
Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997; 276(5312): 561-7.
[http://dx.doi.org/10.1126/science.276.5312.561] [PMID: 9110970]
[62]
Miller J, Dakic A, Chen R, et al. HPV16 E7 protein and hTERT proteins defective for telomere maintenance cooperate to immortalize human keratinocytes. PLoS Pathog 2013; 9(4): e1003284.
[http://dx.doi.org/10.1371/journal.ppat.1003284] [PMID: 23592995]
[63]
Alnafakh RAA, Adishesh M, Button L, Saretzki G, Hapangama DK. Telomerase and telomeres in endometrial cancer. Front Oncol 2019; 9: 344.
[http://dx.doi.org/10.3389/fonc.2019.00344] [PMID: 31157162]
[64]
Buseman CM, Wright WE, Shay JW. Is telomerase a viable target in cancer? Mutat Res 2012; 730(1-2): 90-7.
[http://dx.doi.org/10.1016/j.mrfmmm.2011.07.006] [PMID: 21802433]
[65]
Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 2003; 63(14): 3931-9.
[PMID: 12873987]
[66]
Philippi C, Loretz B, Schaefer UF, Lehr CM. Telomerase as an emerging target to fight cancer - Opportunities and challenges for nanomedicine. J Control Release 2010; 146(2): 228-40.
[http://dx.doi.org/10.1016/j.jconrel.2010.03.025] [PMID: 20381558]
[67]
Vishwakarma K, Bhatt H. Molecular modelling of quinoline derivatives as telomerase inhibitors through 3D-QSAR, molecular dynamics simulation, and molecular docking techniques. J Mol Model 2021; 27(2): 30.
[http://dx.doi.org/10.1007/s00894-020-04648-2] [PMID: 33415518]
[68]
Samad MA, Saiman MZ, Abdul Majid N, Karsani SA, Yaacob JS. Berberine inhibits telomerase activity and induces cell cycle arrest and telomere erosion in colorectal cancer cell line, hct 116. Molecules 2021; 26(2): 376.
[http://dx.doi.org/10.3390/molecules26020376] [PMID: 33450878]
[69]
Dikmen ZG, Gellert GC, Jackson S, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005; 65(17): 7866-73.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-1215] [PMID: 16140956]
[70]
Frink RE, Peyton M, Schiller JH, Gazdar AF, Shay JW, Minna JD. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner. Oncotarget 2016; 7(22): 31639-51.
[http://dx.doi.org/10.18632/oncotarget.9335] [PMID: 27192120]
[71]
Thompson CA, Gu A, Yang S, Mathew V, Fleisig HB, Wong JM. Transient telomerase inhibition alters cell cycle kinetics. BioRxiv 2017; 158287.
[http://dx.doi.org/10.1101/158287]
[72]
Burchett KM, Etekpo A, Batra SK, Yan Y, Ouellette MM. Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells. Oncotarget 2017; 8(48): 83754-67.
[http://dx.doi.org/10.18632/oncotarget.19410] [PMID: 29137380]
[73]
Sadava D, Whitlock E, Kane SE. The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun 2007; 360(1): 233-7.
[http://dx.doi.org/10.1016/j.bbrc.2007.06.030] [PMID: 17585882]
[74]
Seimiya H, Oh-hara T, Suzuki T, et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther 2002; 1(9): 657-65.
[PMID: 12479362]
[75]
Altamura G, degli Uberti B, Galiero G, et al. The small molecule BIBR1532 exerts potential anti-cancer activities in preclinical models of feline oral squamous cell carcinoma through inhibition of telomerase activity and down-regulation of TERT. Front Vet Sci 2021; 7: 620776.
[http://dx.doi.org/10.3389/fvets.2020.620776] [PMID: 33553285]
[76]
Wu ZQ, Guo QL, You QD, Zhao L, Gu HY. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull 2004; 27(11): 1769-74.
[http://dx.doi.org/10.1248/bpb.27.1769] [PMID: 15516720]
[77]
Park SE, Yoo HS, Jin CY, et al. Induction of apoptosis and inhibition of telomerase activity in human lung carcinoma cells by the water extract of Cordyceps militaris. Food Chem Toxicol 2009; 47(7): 1667-75.
[http://dx.doi.org/10.1016/j.fct.2009.04.014] [PMID: 19393284]
[78]
Park DI, Lee JH, Moon SK, et al. Induction of apoptosis and inhibition of telomerase activity by aqueous extract from Platycodon grandiflorum in human lung carcinoma cells. Pharmacol Res 2005; 51(5): 437-43.
[http://dx.doi.org/10.1016/j.phrs.2004.11.003] [PMID: 15749458]
[79]
Ogretmen B, Kraveka JM, Schady D, Usta J, Hannun YA, Obeid LM. Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line. J Biol Chem 2001; 276(35): 32506-14.
[http://dx.doi.org/10.1074/jbc.M101350200] [PMID: 11441001]
[80]
Ogretmen B, Schady D, Usta J, et al. Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem 2001; 276(27): 24901-10.
[http://dx.doi.org/10.1074/jbc.M100314200] [PMID: 11335714]
[81]
Tippani R, Prakhya L, Porika M, Sirisha K, Abbagani S, Thammidala C. Pterostilbene as a potential novel telomerase inhibitor: Molecular docking studies and its in vitro evaluation. Curr Pharm Biotechnol 2014; 14(12): 1027-35.
[http://dx.doi.org/10.2174/1389201015666140113112820] [PMID: 24433502]
[82]
Chen TW, Tsai K, Yang S, et al. Discovery of a novel anti-cancer agent targeting both topoisomerase I & II as well as telomerase activities in human lung adenocarcinoma A549 cells in vitro and in vivo: cinnamomum verum component cuminaldehyde. Curr Cancer Drug Targets 2016; 16(9): 796-806.
[http://dx.doi.org/10.2174/1568009616666160426125526] [PMID: 27113744]
[83]
Taka T, Huang L, Wongnoppavich A, Tam-Chang SW, Lee TR, Tuntiwechapikul W. Telomere shortening and cell senescence induced by perylene derivatives in A549 human lung cancer cells. Bioorg Med Chem 2013; 21(4): 883-90.
[http://dx.doi.org/10.1016/j.bmc.2012.12.020] [PMID: 23321015]
[84]
Li CT, Hsiao YM, Wu TC, Lin Y, Yeh KT, Ko JL. Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells. J Cell Biochem 2011; 112(10): 3044-53.
[http://dx.doi.org/10.1002/jcb.23229] [PMID: 21678477]
[85]
Mender I, Gryaznov S, Dikmen ZG, Wright WE, Shay JW. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2′-deoxyguanosine. Cancer Discov 2015; 5(1): 82-95.
[http://dx.doi.org/10.1158/2159-8290.CD-14-0609] [PMID: 25516420]
[86]
Wang Y, Cheng FX, Yuan XL, et al. Dihydropyrazole derivatives as telomerase inhibitors: Structure-based design, synthesis, SAR and anticancer evaluation in vitro and in vivo. Eur J Med Chem 2016; 112: 231-51.
[http://dx.doi.org/10.1016/j.ejmech.2016.02.009] [PMID: 26900656]
[87]
Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J Urol 2004; 171(5): 1934-8.
[http://dx.doi.org/10.1097/01.ju.0000121329.37206.1b] [PMID: 15076315]
[88]
Nasiri M, Zarghami N, Koshki KN, et al. Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev 2013; 14(6): 3449-53.
[http://dx.doi.org/10.7314/APJCP.2013.14.6.3449] [PMID: 23886126]
[89]
Chen X, Zha GF, Wang JQ, Liu XH. Ethenesulfonyl fluoride derivatives as telomerase inhibitors: Structure-based design, SAR, and anticancer evaluation in vitro. J Enzyme Inhib Med Chem 2018; 33(1): 1266-70.
[http://dx.doi.org/10.1080/14756366.2018.1484735] [PMID: 30139286]
[90]
Hu MH, Lin XT, Liu B, Tan JH. Dimeric aryl-substituted imidazoles may inhibit ALT cancer by targeting the multimeric G-quadruplex in telomere. Eur J Med Chem 2020; 186: 111891.
[http://dx.doi.org/10.1016/j.ejmech.2019.111891] [PMID: 31759730]
[91]
Roe S, Gunaratnam M, Spiteri C, et al. Synthesis and biological evaluation of hybrid acridine-HSP90 ligand conjugates as telomerase inhibitors. Org Biomol Chem 2015; 13(31): 8500-4.
[http://dx.doi.org/10.1039/C5OB01177A] [PMID: 26156660]
[92]
Meng T, Qin QP, Wang ZR, et al. Synthesis and biological evaluation of substituted 3-(2′-benzimidazolyl)coumarin platinum(II) complexes as new telomerase inhibitors. J Inorg Biochem 2018; 189: 143-50.
[http://dx.doi.org/10.1016/j.jinorgbio.2018.09.004] [PMID: 30265997]
[93]
Wei ZZ, Qin QP, Chen JN, Chen ZF. Oxoisoaporphine as potent telomerase inhibitor. Molecules 2016; 21(11): 1534.
[http://dx.doi.org/10.3390/molecules21111534] [PMID: 27854257]
[94]
Herz C, Hertrampf A, Zimmermann S, et al. The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC. J Cell Mol Med 2014; 18(12): 2393-403.
[http://dx.doi.org/10.1111/jcmm.12412] [PMID: 25256442]
[95]
Adler S, Rashid G, Klein A. Indole-3-carbinol inhibits telomerase activity and gene expression in prostate cancer cell lines. Anticancer Res 2011; 31(11): 3733-7.
[PMID: 22110194]
[96]
Akbarizare M, Ofoghi H, Hadizadeh M. Dual effect of Sapogenins extracted from Spirulina platensis on telomerase activity in two different cell lines. Mol Biol Res Commun 2021; 10(1): 1-4.
[http://dx.doi.org/10.22099/MBRC.2020.38230.1537] [PMID: 33681391]
[97]
Tauchi T, Shin-ya K, Sashida G, et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: In vitro and in vivo studies in acute leukemia. Oncogene 2006; 25(42): 5719-25.
[http://dx.doi.org/10.1038/sj.onc.1209577] [PMID: 16652154]
[98]
Chiappori AA, Kolevska T, Spigel DR, et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann Oncol 2015; 26(2): 354-62.
[http://dx.doi.org/10.1093/annonc/mdu550] [PMID: 25467017]
[99]
Akincilar SC, Unal B, Tergaonkar V. Reactivation of telomerase in cancer. Cell Mol Life Sci 2016; 73(8): 1659-70.
[http://dx.doi.org/10.1007/s00018-016-2146-9] [PMID: 26846696]
[100]
Leão R, Apolónio JD, Lee D, Figueiredo A, Tabori U, Castelo-Branco P. Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. J Biomed Sci 2018; 25(1): 22.
[http://dx.doi.org/10.1186/s12929-018-0422-8] [PMID: 29526163]
[101]
Queisser A, Heeg S, Thaler M, von Werder A, Opitz OG. Inhibition of telomerase induces alternative lengthening of telomeres during human esophageal carcinogenesis. Cancer Genet 2013; 206(11): 374-86.
[http://dx.doi.org/10.1016/j.cancergen.2013.10.001] [PMID: 24331919]
[102]
Fujiwara M, Okayasu I, Takemura T, et al. Telomerase activity significantly correlates with chromosome alterations, cell differentiation, and proliferation in lung adenocarcinomas. Mod Pathol 2000; 13(7): 723-9.
[http://dx.doi.org/10.1038/modpathol.3880125] [PMID: 10912930]
[103]
Blackburn EH, Epel ES, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science 2015; 350(6265): 1193-8.
[http://dx.doi.org/10.1126/science.aab3389] [PMID: 26785477]
[104]
Mirjolet C, Boidot R, Saliques S, Ghiringhelli F, Maingon P, Créhange G. The role of telomeres in predicting individual radiosensitivity of patients with cancer in the era of personalized radiotherapy. Cancer Treat Rev 2015; 41(4): 354-60.
[http://dx.doi.org/10.1016/j.ctrv.2015.02.005] [PMID: 25704912]
[105]
Qiang W, Wu Q, Zhou F, Xie C, Wu C, Zhou Y. Suppression of telomere-binding protein TPP1 resulted in telomere dysfunction and enhanced radiation sensitivity in telomerase-negative osteosarcoma cell line. Biochem Biophys Res Commun 2014; 445(2): 363-8.
[http://dx.doi.org/10.1016/j.bbrc.2014.02.001] [PMID: 24513288]
[106]
Röth A, Dürig J, Himmelreich H, et al. Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. Leukemia 2007; 21(12): 2456-62.
[http://dx.doi.org/10.1038/sj.leu.2404968] [PMID: 17898784]
[107]
Shin JS, Foot T, Hong A, et al. Telomerase expression as a predictive marker of radiotherapy response in rectal cancer: In vitro and in vivo study. Pathology 2012; 44(3): 209-15.
[http://dx.doi.org/10.1097/PAT.0b013e3283511cd5] [PMID: 22406483]
[108]
Bejarano L, Bosso G, Louzame J, et al. Multiple cancer pathways regulate telomere protection. EMBO Mol Med 2019; 11(7): e10292.
[http://dx.doi.org/10.15252/emmm.201910292] [PMID: 31273934]
[109]
Sexton AN, Regalado SG, Lai CS, et al. Genetic and molecular identification of three human TPP1 functions in telomerase action: recruitment, activation, and homeostasis set point regulation. Genes Dev 2014; 28(17): 1885-99.
[http://dx.doi.org/10.1101/gad.246819.114] [PMID: 25128433]
[110]
Shi Y, Li X, Ran L, et al. Study on the status of thyroid function and thyroid nodules in chinese breast cancer patients. Oncotarget 2017; 8(46): 80820-5.
[http://dx.doi.org/10.18632/oncotarget.20542] [PMID: 29113346]
[111]
Wang F, Podell ER, Zaug AJ, et al. The POT1–TPP1 telomere complex is a telomerase processivity factor. Nature 2007; 445(7127): 506-10.
[http://dx.doi.org/10.1038/nature05454] [PMID: 17237768]
[112]
Beisner J, Dong M, Taetz S, et al. Nanoparticle mediated delivery of 2′-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells. Lung Cancer 2010; 68(3): 346-54.
[http://dx.doi.org/10.1016/j.lungcan.2009.07.010] [PMID: 19695733]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy